Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

CTIX May 21st “Understanding QIDP and Other 21st Century Incentives for Developing and Marketing Anti-Infective Medicines,” on May 21, 2015 at the New York Palace Hotel.

This investor event will be focused on the positive impact of the GAIN Act and the QIDP designation on investments in companies with anti-infective programs. The event is designed to help investors understand how leveraging various regulatory and commercial incentives translate to increased shareholder value. Speakers will include regulatory attorneys, legislators, industry executives and medical professionals. Investors interested in attending should contact Tirth Patel of Tiberend Strategic Advisors, Inc.: [e-mail].

To access the webcast go to: http://psav.rampard.com/20150521/


web cast sponsored by Cellceutix, CoreMedix & NEXGEN Biosciences. starts 8am 5/21/15

webcast link
http://psav.rampard.com/20150521/reg.jsp


http://50.87.248.71/~cormedix/wp-content/uploads/2014/11/QIDP-Formal-Invite-2-435x1024.jpg

==============================================
Posted by 'farrell90'...

Power point presentation on CTIX web page.

http://cellceutix.com/wp-content/uploads/2014/06/QIDP_21May2015-Power-Point-Presentation.pdf

Recounts Brilacidin information previously released.

Gram negative drug has the potential to be another big winner,CC-1807

New information regarding the gram negative drug: CC-1807 being optimized for urinary tract infections, bacteremia and lung infections {pneumonia}

Optimized for expanded Gram neg coverage to include Pseudomonas and Acineobacter

From power point:

Gram-negative activity evident in several structural series of small nonpeptidic mimetics of host defense proteins

2 series show low cytotoxicity, favorable PK properties and robust efficacyin vitro and in vivo against Enterobacteriaceae organisms

CC-1807 is potently active against clinical isolates of E. coli, K. pneumoniae and E. cloacae, including MDR CRE strains

Additional preclinical efficacy studies with CC-1807 are in progress

Dose optimization in lung infection models UTI and bacteremia

Chemical optimization of CC-1807 and additional analogs is continuing
Expand coverage to Pseudomonas and Acinetobacter spp

===================================================

Thanks again to Chem for the heads up!